A new study, below [1] & [2].
In 2004 I came across old studies that showed that ADT promotes changes to the androgen receptor [AR] environment. At diagnosis, the AR is invariably "wild type". When ADT failed, AR gene amplification was common. True mutations were rare.
{This was sufficient for me to delay Lupron as long as I could (I still haven't used it, but I do use DES [Diethylstilbestrol]) and to develop the hypothesis that periodic testosterone replacement might be useful during ADT, to reverse adaptations.}
The irony is that the AR - normal at diagnosis - remains the ultimate target of AR-axis therapies - even though success is short-lived imo.
With more aggressive AR-axis treatments, AR splice variants such as ARV7 have became common.
The ultimate response to very aggressive AR-axis therapies, is a retreat into a stem cell-like state (i.e. without AR). And neuroendocrine PCa [NEPC] has thus become more common.
In castrate-resistant [CRPC] intervention studies, and even those involving hormone-sensitive metastatic cases, there is little need for a surrogate for overall survival. But in local hormone-sensitive PCa, overall survival times can be lengthy. The "time to biochemical recurrence" [TTBCR] has been used as a surrogate. The idea being that if a treatment is effective for a longer period, overall survival will be correspondingly longer.
My problem with this is that treatment itself results in treatment-emergent states that tend to reduce post-treatment survival. The cost of increasing treatment-effective durations is the creation of a more aggressive disease. Therefore, one must be careful when using "time to biochemical recurrence" as a surrogate for increased survival time.
"In a recent study published in the Journal of Clinical Oncology, researchers found that biochemical recurrence (BCR) was not a reliable surrogate end point for overall survival (OS) in patients with localized prostate cancer(PCa)." [2]
"Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained." [1]
"TTBCR was measured as the time from random assignment to BCR or the onset of ADT without recurrence or any cancer-specific death. Biochemical recurrence-free survival (BCRFS) was defined as the time from random assignment to BCR or death of any kind. OS refers to the time from random assignment to death." [2]
"Although BCRFS and TTBCR are prognostic, neither measure successfully met the surrogacy criteria. ...
“Overall, these results strongly suggest that BCR-based end points should not be the primary end point of any randomized trial in localized PCa.”"
-Patrick